FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005628652> ?p ?o ?g. }

• W3005628652 abstract "Background Clopidogrel nonresponsiveness is a prognostic marker after percutaneous coronary intervention. Prasugrel and ticagrelor provide a better platelet inhibition and represent the first‐line antiplatelet treatment in acute coronary syndrome. We sought to assess the prognostic impact of high platelet reactivity (HPR) and the potential clinical benefit of a “tailored” escalated or changed antiplatelet therapy in patients with chronic total occlusion. Methods and Results From Florence CTO‐PCI (chronic total occlusion‐percutaneous coronary intervention) registry, platelet function assessed by light transmission aggregometry, was available for 1101 patients. HPR was defined by adenosine diphosphate test ≥70% and optimal platelet reactivity by adenosine diphosphate test <70%. The endpoint of the study was long‐term cardiac survival. Patients were stratified according to light transmission aggregometry results: optimal platelet reactivity (82%) and HPR (18%). Means for the adenosine diphosphate test were 44±16% versus 77±6%, respectively. Three‐year survival was significantly higher in the optimal platelet reactivity group compared with HPR patients (95.3±0.8% versus 86.2±2.8%; P <0.001). With the availability of new P2Y 12 inhibitors, a deeper platelet inhibition (46±17%) and similar survival to the optimal platelet reactivity group were achieved in patients with HPR on clopidogrel therapy after escalation. Conversely, HPR on clopidogrel therapy “not switched” was associated with cardiac mortality (hazard ratio 2.37; P =0.003) after multivariable adjustment. Conclusions HPR on treatment could be a modifiable prognostic marker by new antiaggregants providing a deeper platelet inhibition associated with clinical outcome improvement in complex chronic total occlusion patients. A “tailored” antiplatelet therapy, also driven by the entity of platelet inhibition, could be useful in these high risk setting patients." @default.
• W3005628652 created "2020-02-24" @default.
• W3005628652 creator A5004032203 @default.
• W3005628652 creator A5006597199 @default.
• W3005628652 creator A5011842156 @default.
• W3005628652 creator A5041234215 @default.
• W3005628652 creator A5060506721 @default.
• W3005628652 creator A5068485330 @default.
• W3005628652 creator A5070057174 @default.
• W3005628652 creator A5074401377 @default.
• W3005628652 creator A5074845499 @default.
• W3005628652 creator A5076179755 @default.
• W3005628652 date "2020-02-18" @default.
• W3005628652 modified "2023-10-18" @default.
• W3005628652 title "Clinical Implications of “Tailored” Antiplatelet Therapy in Patients With Chronic Total Occlusion" @default.
• W3005628652 cites W144700851 @default.
• W3005628652 cites W1524651077 @default.
• W3005628652 cites W156743206 @default.
• W3005628652 cites W1634973131 @default.
• W3005628652 cites W1726466368 @default.
• W3005628652 cites W1936833235 @default.
• W3005628652 cites W1974655135 @default.
• W3005628652 cites W1982882705 @default.
• W3005628652 cites W2029179690 @default.
• W3005628652 cites W2039084654 @default.
• W3005628652 cites W2060063218 @default.
• W3005628652 cites W2062398036 @default.
• W3005628652 cites W2063658366 @default.
• W3005628652 cites W2087150869 @default.
• W3005628652 cites W2092944887 @default.
• W3005628652 cites W2100209149 @default.
• W3005628652 cites W2103688147 @default.
• W3005628652 cites W2105310708 @default.
• W3005628652 cites W2116457054 @default.
• W3005628652 cites W2120989063 @default.
• W3005628652 cites W2121205446 @default.
• W3005628652 cites W2125173296 @default.
• W3005628652 cites W2130350603 @default.
• W3005628652 cites W2140501627 @default.
• W3005628652 cites W2145126811 @default.
• W3005628652 cites W2145323902 @default.
• W3005628652 cites W2151850422 @default.
• W3005628652 cites W2157833432 @default.
• W3005628652 cites W2165620610 @default.
• W3005628652 cites W2169387542 @default.
• W3005628652 cites W2480337301 @default.
• W3005628652 cites W2509918966 @default.
• W3005628652 cites W2518708201 @default.
• W3005628652 cites W2566087446 @default.
• W3005628652 cites W2748517697 @default.
• W3005628652 cites W2766257307 @default.
• W3005628652 cites W2887919176 @default.
• W3005628652 cites W2916193025 @default.
• W3005628652 doi "https://doi.org/10.1161/jaha.119.014676" @default.
• W3005628652 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7070214" @default.
• W3005628652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32067582" @default.
• W3005628652 hasPublicationYear "2020" @default.
• W3005628652 type Work @default.
• W3005628652 sameAs 3005628652 @default.
• W3005628652 citedByCount "8" @default.
• W3005628652 countsByYear W30056286522021 @default.
• W3005628652 countsByYear W30056286522022 @default.
• W3005628652 crossrefType "journal-article" @default.
• W3005628652 hasAuthorship W3005628652A5004032203 @default.
• W3005628652 hasAuthorship W3005628652A5006597199 @default.
• W3005628652 hasAuthorship W3005628652A5011842156 @default.
• W3005628652 hasAuthorship W3005628652A5041234215 @default.
• W3005628652 hasAuthorship W3005628652A5060506721 @default.
• W3005628652 hasAuthorship W3005628652A5068485330 @default.
• W3005628652 hasAuthorship W3005628652A5070057174 @default.
• W3005628652 hasAuthorship W3005628652A5074401377 @default.
• W3005628652 hasAuthorship W3005628652A5074845499 @default.
• W3005628652 hasAuthorship W3005628652A5076179755 @default.
• W3005628652 hasBestOaLocation W30056286521 @default.
• W3005628652 hasConcept C126322002 @default.
• W3005628652 hasConcept C164705383 @default.
• W3005628652 hasConcept C207103383 @default.
• W3005628652 hasConcept C2777028646 @default.
• W3005628652 hasConcept C2777628954 @default.
• W3005628652 hasConcept C2777849778 @default.
• W3005628652 hasConcept C2780400711 @default.
• W3005628652 hasConcept C2780890252 @default.
• W3005628652 hasConcept C44249647 @default.
• W3005628652 hasConcept C49059817 @default.
• W3005628652 hasConcept C500558357 @default.
• W3005628652 hasConcept C71924100 @default.
• W3005628652 hasConcept C89560881 @default.
• W3005628652 hasConceptScore W3005628652C126322002 @default.
• W3005628652 hasConceptScore W3005628652C164705383 @default.
• W3005628652 hasConceptScore W3005628652C207103383 @default.
• W3005628652 hasConceptScore W3005628652C2777028646 @default.
• W3005628652 hasConceptScore W3005628652C2777628954 @default.
• W3005628652 hasConceptScore W3005628652C2777849778 @default.
• W3005628652 hasConceptScore W3005628652C2780400711 @default.
• W3005628652 hasConceptScore W3005628652C2780890252 @default.
• W3005628652 hasConceptScore W3005628652C44249647 @default.
• W3005628652 hasConceptScore W3005628652C49059817 @default.
• W3005628652 hasConceptScore W3005628652C500558357 @default.
• W3005628652 hasConceptScore W3005628652C71924100 @default.
• W3005628652 hasConceptScore W3005628652C89560881 @default.

• next